Researchers at the University of Cambridge and spin-out DIOSynVax completed the first human clinical trial of a universal vaccine targeting Sarbeco coronaviruses, a group that includes SARS-CoV-2 and closely related bat viruses. The early results emphasize safety while establishing a clinical proof point for broad coronavirus coverage beyond strain-specific approaches, setting the stage for further study of durability and immunogenicity breadth.